Latest Biotechnology News

Page 1 of 66
The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.
Logan Eniac
Logan Eniac
14 Feb 2026
Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
Logan Eniac
14 Feb 2026
Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
Ada Torres
12 Feb 2026
Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.
Ada Torres
Ada Torres
12 Feb 2026
Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.
Ada Torres
Ada Torres
12 Feb 2026
Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.
Victor Sage
Victor Sage
11 Feb 2026
Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.
Ada Torres
Ada Torres
11 Feb 2026
Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.
Ada Torres
Ada Torres
11 Feb 2026
Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.
Ada Torres
Ada Torres
11 Feb 2026
PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.
Ada Torres
Ada Torres
9 Feb 2026
Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.
Ada Torres
Ada Torres
9 Feb 2026